Skip to main content

Patents on Inventions Involving AI in the Life Sciences and Healthcare

  • Chapter
  • First Online:
The Future Circle of Healthcare

Part of the book series: Future of Business and Finance ((FBF))

  • 725 Accesses

Abstract

In recent years, the relevance of artificial intelligence (AI) and its potential applications in various technical areas of the life sciences and healthcare have increased. The accumulation of big data, the development of algorithms, and improvements in computer processing capacity have made possible the integration of AI in the life sciences and healthcare. Some examples of AI applications in these fields are drug and molecular design, the prediction of disease risk, diagnosis of diseases, detection of cancerous cells and tumors, genomics, the monitoring of therapeutic progress, the adjustment of therapeutic treatment, and improvements in manufacturing processes. Such applications change the mode of work in hospitals and for doctors and give rise to interdisciplinary products for which a company seeks a monopoly under patent law. A patented technical monopoly may facilitate a company a dominant market position and a return on investment. However, a patent monopoly is subject to legal regulations that define the preconditions for a patent grant as well as exclusion criteria. These may vary in the particular country for which a patent is sought. This chapter is based on the European Patent Convention (EPC) and the case law of the Boards of Appeal of the European Patent Office (EPO). The examples of granted or refused patents presented here may be assessed differently by other jurisdictions [e.g., the United States Patent and Trademark Office (USPTO), Japan Patent Office (JPO), China National Intellectual Property Administration (CNIPA)].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    The official English translation of the Paris Convention for the Protection of Industrial Property is available at the URL: https://wipolex.wipo.int/en/text/288514

  2. 2.

    For the EPO, see EPC, Article 58, Entitlement to file a European patent application, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar58.html

  3. 3.

    EPC, Article 60, Right to a European patent, https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/ar60.html

  4. 4.

    EPC, Article 62 and Article 81, Right of the inventor to be mentioned and Designation of the inventor, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar62.html and https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/ar81.html

  5. 5.

    EPC, Article 63, Term of the European patent, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar63.html

  6. 6.

    For further information: https://ec.europa.eu/growth/industry/strategy/intellectual-property/patent-protection-eu/supplementary-protection-certificates-pharmaceutical-and-plant-protection-products_en

  7. 7.

    EPC, Article 69, Extent of protection, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar69.html

  8. 8.

    EPC, Article 84, Claims, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar84.html

  9. 9.

    EPC, Article 64, Rights conferred by a European patent, https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/ar64.html; and national patent law.

  10. 10.

    EPC: Article 52 (Patentable inventions, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar52.html), Article 54 (Novelty, https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/ar54.html), Article 56 (Inventive step, https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/ar56.html), and Article 57 (Industrial application, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar57.html)

  11. 11.

    EPC, Article 83, Disclosure of the invention, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar83.html

  12. 12.

    EPC, Article 53, Exceptions to patentability, https://www.epo.org//law-practice/legal-texts/html/epc/2020/e/ar53.html

  13. 13.

    EPC, Article 52, Patentable inventions, https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar52.html

  14. 14.

    https://www.epo.org/news-events/in-focus/ict/artificial-intelligence.html

  15. 15.

    EPO, Guidelines for Examination, Part G, Chap. II, Sect. 3.3.1, Discoveries, https://www.epo.org/law-practice/legal-texts/html/guidelines/e/g_ii_3_1.htm

  16. 16.

    EPO, Guidelines for Examination, Part F, Chap. IV, Sect. 3.9, Claims directed to computer-implemented inventions, https://www.epo.org/law-practice/legal-texts/html/guidelines/e/f_iv_3_9.htm

  17. 17.

    EPO, Guidelines for Examination, Part G, Chap. II, Sect. 3.3.1 (Artificial intelligence and machine learning, https://www.epo.org/law-practice/legal-texts/html/guidelines/e/g_ii_3_3_1.htm) and 3.3.2 (Simulation, design or modeling, https://www.epo.org/law-practice/legal-texts/html/guidelines/e/g_ii_3_3_2.htm)

  18. 18.

    EPO, Guidelines for Examination, Part G, Chap. II, Sect. 3.3, Mathematical models, https://www.epo.org/law-practice/legal-texts/html/guidelines/e/g_ii_3_3.htm

  19. 19.

    EPO, T 1227/05 (Circuit simulation I/Infineon Technologies) of 13.12.2006, https://www.epo.org/law-practice/case-law-appeals/recent/t051227ep1.html

  20. 20.

    EPO, T 1358/09 (Classification/BDGB ENTERPRISE SOFTWARE) of 21.11.2014, https://www.epo.org/law-practice/case-law-appeals/recent/t091358eu1.html

  21. 21.

    https://www.epo.org/law-practice/legal-texts/html/guidelines/e/g_ii_3_3.htm

  22. 22.

    EPC, Article 84, Claims, https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/ar84.html

  23. 23.

    EPO, T 1285/10 (Genetic analysis computing system/Iris Biotechnologies) of 23.5.2014, https://www.epo.org/law-practice/case-law-appeals/recent/t101285eu1.html

  24. 24.

    Figure 1 on page 22 is available online: https://worldwide.espacenet.com/patent/search/family/022537965/publication/EP1222602B1?q=EP1222602B1

  25. 25.

    EPC, Article 83, Disclosure of the invention, https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/ar83.html

  26. 26.

    B1 represents the granted patent as decided by the examination division and B2 represented the patent maintained as amended during an opposition filed by a third party, The detailed proceedings of T 0466/09 are available under the following URL: https://register.epo.org/application?number=EP97904470

  27. 27.

    A1, A2, or A3 at the end of a patent number represents a published patent application, for detailed explanation see URL: https://www.epo.org/searching-for-patents/helpful-resources/first-time-here/definitions.html

  28. 28.

    https://worldwide.espacenet.com/patent/search/family/038023611/publication/EP1955228A2?q=EP1955228; The original German wording of the patent application has been translated into English.

  29. 29.

    The references refers to the downloaded document which is available under the following URL: https://worldwide.espacenet.com/patent/search/family/038023611/publication/EP1955228A2?q=EP1955228

  30. 30.

    The decision is available only in German under URL: https://www.epo.org/law-practice/case-law-appeals/recent/t180161du1.html, the following references are made based on the available online version.

  31. 31.

    The complete claim URL: https://www.epo.org/law-practice/case-law-appeals/recent/t191191eu1.html

  32. 32.

    Fig. 1, page 13, paras [0055] and [0056] of EP2351523A1, https://worldwide.espacenet.com/patent/search/family/042128288/publication/EP2351523A1?q=EP2351523A1

  33. 33.

    Reason 4.1 of T 161/18 https://www.epo.org/law-practice/case-law-appeals/recent/t191191eu1.html

  34. 34.

    EPC, Article 54, Novelty.

  35. 35.

    EPC, Article 56, Inventive step, https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/ar56.html

  36. 36.

    The wording of the claims is available under the URL and the numbers are explained in the description of the patent application:

    https://worldwide.espacenet.com/patent/search/family/022627891/publication/EP1247229B1?q=EP1247229b1

  37. 37.

    EPO, decision T 0927/14, T 0927/14 (Wireless patient monitoring/Philips) of 20.2.2019, https://www.epo.org/law-practice/case-law-appeals/recent/t140927eu1.html

  38. 38.

    See Reason 7.4 and 8. of the decision: https://www.epo.org/law-practice/case-law-appeals/recent/t140927eu1.html

  39. 39.

    All of the EP patents and applications mentioned in this section can be viewed online at Espacenet (https://worldwide.espacenet.com/patent/), as can any patent application from non-European countries. For that purpose, please, just copy in the cited number.

  40. 40.

    Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:31998L0044

  41. 41.

    Article 6 of Directive 98/44/EC.

  42. 42.

    EPC, Rule 28, Exceptions to patentability, https://www.epo.org/law-practice/legal-texts/html/epc/2020/e/r28.html

  43. 43.

    For example, in Germany, paragraph 13 sec. 1 of the German Patent Act stipulates that (English translation) “The patent shall not take effect if the Federal Government orders that the invention be used in the interest of public welfare. Furthermore, it shall not extend to a use of the invention ordered in the interest of federal security by the competent supreme federal authority or by a subordinate agency on its behalf.”

  44. 44.

    Statement by Moderna on Intellectual Property Matters during the COVID-19 Pandemic (10/08/2020); available under the URL: https://investors.modernatx.com/Statements%2D%2DPerspectives/Statements%2D%2DPerspectives-Details/2020/Statement-by-Moderna-on-Intellectual-Property-Matters-during-the-COVID-19-Pandemic/default.aspx

  45. 45.

    Press release: https://www.wto.org/english/news_e/news22_e/mc12_17jun22_e.htm

  46. 46.

    Press release: https://www.biodeutschland.org/en/press-releases/biotechnology-industry-regrets-wto-decision-on-patent-suspensions.html

  47. 47.

    Kluwer Patent Blog “Covid-19 ‘Patent Waiver’: revolution or tempest in a glass of water?”, Matthieu Dhenne, http://patentblog.kluweriplaw.com/2022/06/22/covid-19-patent-waiver-revolution-or-storm-in-a-glass-of-water/

  48. 48.

    https://dermanostic.com/

  49. 49.

    CAR = chimeric antigen receptor; CAR T-cells = T immune cells expressing a CAR.

  50. 50.

    For more details, see AIDPATH (https://www.sciencrew.com/c/6499?title=AIDPATH)

References

Download references

Acknowledgments

Many thanks to my colleague and friend, Benjamin Petri, who is a German and European Patent Attorney with profound experiences on computer implemented inventions for discussions on AI definitions. The author declares no potential conflicts of interest. The views expressed in this chapter do not necessarily reflect those of the author’s organization.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anna Katharina Heide .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Heide, A.K. (2022). Patents on Inventions Involving AI in the Life Sciences and Healthcare. In: Ehsani, S., Glauner, P., Plugmann, P., Thieringer, F.M. (eds) The Future Circle of Healthcare. Future of Business and Finance. Springer, Cham. https://doi.org/10.1007/978-3-030-99838-7_9

Download citation

Publish with us

Policies and ethics